FDA Product Promotion Regs Shouldn’t Stop Companies From Challenging CER Results, Official Says
This article was originally published in The Pink Sheet Daily
FDA’s Bob Temple dismisses the notion that drug companies, even with FDA’s regulation of product promotions, do not have the ability to challenge comparative effectiveness research findings they believe to be false or misleading. He says FDA is in no way trying to “deny them that right.”
You may also be interested in...
Health care economic information that is disseminated to formulary committees must be based on “competent and reliable scientific evidence.” Yet FDA has traditionally applied a more restrictive “substantial evidence” standard in its enforcement approach, said panelists at a recent conference, who questioned whether the growing government involvement in funding comparative effectiveness research would change this approach.
With the Patient-Centered Outcomes Research Institute beginning the early grant process and other data collection initiatives such as FDA’s Sentinel and Janus programs also underway, National Pharmaceutical Council Chief Science Officer Robert Dubois is recommending changes in policy that will allow equal access for industry and academia to data used in comparative effectiveness studies.
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.